Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe.

Jager, Kitty J.; Kramer, Anneke; Chesnaye, Nicholas C.; Couchoud, Cécile; Sánchez-Álvarez, J. Emilio; Garneata, Liliana; Collart, Fréderic; Hemmelder, Marc H.; Ambühl, Patrice; Kerschbaum, Julia; Legeai, Camille; Dolores del Pino y Pino, María; Mircescu, Gabriel; Mazzoleni, Lionel; Hoekstra, Tiny; Winzeler, Rebecca; Mayer, Gert; Stel, Vianda S.; Wanner, Christoph; Zoccali, Carmine; Massy, Ziad A.

The aim of this study was to investigate 28-day mortality after COVID-19 diagnosis in the European kidney replacement therapy population. In addition, we determined the role of patient characteristics, treatment factors, and country on mortality risk using ERA-EDTA Registry data on patients receiving kidney replacement therapy in Europe between February 1, 2020 and April 30, 2020. Additional data on all patients with a diagnosis of COVID-19 were collected from seven European countries encompassing 4298 patients. COVID-19 attributable mortality was calculated using propensity-score matched historic controls and after 28 days of follow-up was 20.0% (95% confidence interval 18.7%-21.4%) in 3285 patients receiving dialysis, and 19.9% (17.5%-22.5%) in 1013 recipients of a transplant. We identified differences in COVID-19 mortality across countries, and an increased mortality risk in older patients receiving kidney replacement therapy and male patients receiving dialysis. In recipients of kidney transplants older than 75 years of age 44.3% (35.7%-53.9%) did not survive COVID-19. Mortality risk was 1.28 (1.02-1.60) times higher in transplant recipients compared with matched dialysis patients. Thus, the pandemic has had a substantial effect on mortality in patients receiving kidney replacement therapy; a highly vulnerable population due to underlying chronic kidney disease and high prevalence of multimorbidity.